Cidara Therapeutics, Inc. — Director's Dealing 2021

Jul 6, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Cidara Therapeutics, Inc. (CDTX)
CIK: 0001610618
Period of Report: 2021-07-01

Reporting Person: Tari Leslie (Chief Scientific Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2551	Direct
Common Stock	13298	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$2.29	2024-09-08	Common Stock (30708)		Direct
Stock Option (right to buy)	$2.45	2026-12-17	Common Stock (49739)		Direct
Stock Option (right to buy)	$2.45	2026-12-17	Common Stock (79221)		Direct
Stock Option (right to buy)	$1.98	2030-03-18	Common Stock (85000)		Direct
Stock Option (right to buy)	$2.55	2031-03-16	Common Stock (120000)		Direct
Restricted Stock Unit	$	2022-01-01	Common Stock (3675)		Direct
Stock Option (right to buy)	$2.45	2026-12-17	Common Stock (918)		Indirect
Stock Option (right to buy)	$2.45	2026-12-17	Common Stock (3927)		Indirect
Stock Option (right to buy)	$1.98	2030-03-18	Common Stock (521)		Indirect
Stock Option (right to buy)	$2.55	2031-03-16	Common Stock (104)		Indirect

Footnotes

F1: Shares are fully vested

F2: One-third (1/3) of the shares subject to the option vested on December 18, 2020 and the remainder vests and becomes exercisable in a series of twenty-four (24) successive equal monthly installments thereafter until fully vested on December 18, 2022.

F3: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020.

F4: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021.

F5: The shares shall vest upon the achievement of various clinical and corporate milestones.

F6: Restricted stock units convert into common stock on a one-for-one basis.